Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | HRH2 | P25021 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6604508 | 0.88 | KDM4E (0.80) | GAAKDM4ETDP1TRPV6KMT2A | |
| SCHEMBL26702308 | 0.87 | TRPV6 (0.67) | GAAKDM4ETDP1TRPV6KMT2A | |
| SCHEMBL1427564 | 0.86 | KDM4E (0.83) | KDM4ETDP1TRPV6KMT2AMEN1 | |
| SCHEMBL18227502 | 0.84 | KDM4E (0.61) | GAAKDM4ETDP1TRPV6KMT2A | |
| SCHEMBL19869945 | 0.83 | GAA (0.63) | GAAKDM4ETDP1LMNAMAPK1 | |
| SCHEMBL24192354 | 0.83 | ALDH1A1 (0.51) | GAAKDM4ETDP1TRPV6POLB | |
| SCHEMBL19086425 | 0.82 | KDM4E (0.61) | GAAKDM4ETDP1TRPV6KMT2A | |
| SCHEMBL2075627 | 0.82 | NR1H2 (0.59) | GAAKDM4ETDP1KMT2AMEN1 | |
| SCHEMBL4591936 | 0.81 | KDM4E (0.70) | GAAKDM4ETDP1TRPV6KMT2A | |
| SCHEMBL19869936 | 0.81 | TRPV6 (0.52) | GAAKDM4ETDP1TRPV6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11603349-B2 | Anti-fibrotic compounds | CERTA THERAPEUTICS PTY LTD (AU) | 2023-03-14 | — | — | US | disclosed |
| EP-3265453-B1 | NEW PYRIDINONES AND ISOQUINOLINONES AS INHIBITORS OF THE BROMODOMAIN BRD9 | BOEHRINGER INGELHEIM INT (DE) | 2022-06-29 | — | — | EP | disclosed |
| US-11319318-B2 | Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-03 | — | — | US | disclosed |
| US-20210246100-A1 | ANTI-FIBROTIC COMPOUNDS | CERTA THERAPEUTICS PTY LTD (AU) | 2021-08-12 | — | — | US | disclosed |
| US-20210246100-A1 | ANTI-FIBROTIC COMPOUNDS | CERTA THERAPEUTICS PTY LTD (AU) | 2021-08-12 | — | — | US | disclosed |
| US-11014873-B2 | Anti-fibrotic compounds | CERTA THERAPEUTICS PTY LTD. (AU) | 2021-05-25 | — | — | US | disclosed |
| US-11014873-B2 | Anti-fibrotic compounds | CERTA THERAPEUTICS PTY LTD. (AU) | 2021-05-25 | — | — | US | disclosed |
| US-20200055814-A1 | ANTI-FIBROTIC COMPOUNDS | SHIRE HUMAN GENETIC THERAPIES, INC. | 2020-02-20 | — | — | US | disclosed |
| US-20200055814-A1 | ANTI-FIBROTIC COMPOUNDS | SHIRE HUMAN GENETIC THERAPIES, INC. | 2020-02-20 | — | — | US | disclosed |
| CN-110546133-A | Anti-fibrotic compounds | SHIRE HUMAN GENETIC THERAPIES | 2019-12-06 | — | — | CN | disclosed |
| WO-2018144620-A9 | ANTI-FIBROTIC COMPOUNDS | CERTA THERAPEUTICS PTY LTD. (AU) | 2019-01-24 | — | — | WO | disclosed |
| WO-2018144620-A9 | ANTI-FIBROTIC COMPOUNDS | CERTA THERAPEUTICS PTY LTD. (AU) | 2019-01-24 | — | — | WO | disclosed |
| WO-2018144620-A1 | ANTI-FIBROTIC COMPOUNDS | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2018144620-A1 | ANTI-FIBROTIC COMPOUNDS | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2018-08-09 | — | — | WO | disclosed |
| US-20180044335-A1 | New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-15 | — | — | US | disclosed |
| US-20180044335-A1 | New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11603349-B2 | Anti-fibrotic compounds | TGFB1, SMAD3, TGFB2 | GAA 1453/4885KDM4E 4055/4885TDP1 3820/4885 |
| US-20180044335-A1 | New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 | BRD9, BRD1, BRD2 | GAA 4237/4885KDM4E 1154/4885TDP1 1473/4885 |
| US-20210246100-A1 | ANTI-FIBROTIC COMPOUNDS | TGFB1, SMAD3, TGFB2 | GAA 1453/4885KDM4E 4055/4885TDP1 3820/4885 |
| US-11014873-B2 | Anti-fibrotic compounds | TGFB1, SMAD3, SMAD2 | GAA 1356/4885KDM4E 4041/4885TDP1 3731/4885 |
| US-11319318-B2 | Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 | BRD9, BRD1, BRD2 | GAA 4152/4885KDM4E 1262/4885TDP1 1708/4885 |
| US-20200055814-A1 | ANTI-FIBROTIC COMPOUNDS | TGFB1, SMAD3, SMAD2 | GAA 2094/4885KDM4E 3305/4885TDP1 3895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.